54 results about "Benzodioxan" patented technology

Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

The invention provides a compound inflaming retarding masterbatch and a preparation method of the compound inflaming retarding masterbatch. The inflaming retarding masterbatch is formed by mixing carrier resin, a compound fire retardant, a lubrication dispersing agent and antioxygen. The method comprises the following steps of: mixing 1,2-Bis(2,3,4,5,6-pentabromophenyl)ethane, antimonous oxide, zinc borate, linear thermoplastic phenolic resin powder, adding a silane coupling agent for mixing to obtain the compound fire retardant; adding the dried carrier resin, the compound fire retardant, the lubrication dispersing agent and the antioxygen in a high-speed mixer for mixing, extruding, prilling and drying to prepare the compound inflaming retarding masterbatch. The diphenylethane decabromide serves as a main fire retardant which contains halogen and does not contain toxin, no poisonous polybrominated dibenzodioxins or polybrominated dibenzofurans are produced during burning, and simultaneously low-price zinc borate partially replaces expensive antimonous oxide, so that the compound inflaming retarding masterbatch has price superiorities, effectively reduces density of smoke obtained during burning simultaneously and restrains drop caused by burning and fusing. Synergistic effects of a compound inflaming retarding system greatly improve inflaming retarding efficiency of the compound inflaming retarding masterbatch.

The invention relates to a compounding flame retardation polystyrene composition and a preparation method thereof. The composition comprises polystyrene resin, complex flame retardant, lubrication dispersant, flexibilizer and anti-oxidant. The method comprises the steps of: adding all the components into a high speed mixer, mixing the components uniformly, extruding the mixed components by using a double-screw extruder, and granulating the mixed components by using a pelleter to obtain polystyrene composition pellets. According to the invention, compounding is carried out by using environment-friendly decabromodiphenylethane, antimony trioxide, zinc borate and thermoplastic phenol resins; toxic polybrominated dibenzdioxan and toxic polybrominated dibenzofurans are not generated when combustion of the composition is carried out; relatively expensive antimony trioxide is partially replaced by cheap zinc borate; not only price is low, but also smoke concentration in combustion process can be effectively reduced, and combustion molten drops are inhibited, thereby synergistic flame retardation effect of the compounding flame retardant is obvious, and flame retardation effect is good.

The present invention relates to phosphoric acid / phosphonic acid derivatives shown by formula (I), wherein, R1 or R2 represents the following structures: (Q1), or (Q2), or (Q3). Q1 represents ester derivatives of L-amino acid, wherein R3 is alkyl with 1-6 carbon atoms or cycloalkyl, R4 is H or alkyl with 1-6 carbon atoms; Q2 represents hydroxyl substituted benzodioxane derivatives; Q3 represents hydroxyl substituted benzodioxolane derivatives; R1 or R2 is the same or different, but at least one of them is Q2 or Q3; D represents residues of pharmacologically active molecules containing a phosphate / phosphonate group, i.e. formula (II) represents pharmacologically active molecules containing a phosphate / phosphonate group; and when R1 and R2 are different, the configuration of the P atom connected to R1 and R2 is of R or S type.

The invention discloses 1,4-benzodioxan-containing 1,3,4-oxadiazole derivatives. The 1,4-benzodioxan-containing 1,3,4-oxadiazole derivatives have the general formula shown in the patent specification, wherein R represents a group shown in the patent specification. The 1,4-benzodioxan-containing 1,3,4-oxadiazole derivatives have obvious effects for inhibiting growth of a human hepatoma cell HEP-G2, a human colon cancer cell SW116 and a human cervical cancer cell HELA and thus the 1,4-benzodioxan-containing 1,3,4-oxadiazole derivatives can be used in preparation of anti-cancer drugs. The invention also discloses a preparation method of the 1,4-benzodioxan-containing 1,3,4-oxadiazole derivatives.

An object of the invention is to provide a manufacturing method of an organic EL display device by fabricating a low molecular weight light emitting material on a lower electrode of an organic EL display device by an inkjet method. In order to achieve this object, in an organic EL display device including an organic material layer, the organic material layer is configured of a mixture of a low molecular weight material and a specified organic material. Concretely, at least one compound selected from 1,2,3-trimethoxytoleune, 1,2,3, 5-tetramethoxybenzene, 1,2-dimethoxy-5-bromobenzene, 3,4-dimethoxy-6-bromotoluene, 1,2,3-trimethoxy-5-bromo-benzene, and 3-bromo-1,2-benzodioxane is contained.

Processes for preparing N-aryl-piperazine derivatives of formula I particularly (R)-4-cyano-N-[2-[4-(2,3-dihydro-1,4-benzodioxan-5-yl)-1-piperazinyl-propyl]-N-(2-pyridinyl)-benzamide, are disclosed. Compositions comprising N-aryl-piperazine derivatives and low levels of common impurities are also disclosed. In addition, products produced by the process are disclosed.

Compounds of the Formula:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

By using a charge-transporting thin film which is made of charge-transporting varnish containing, as an electron-acceptor material, a 1,4-benzodioxane sulfonic acid compound represented by the formula (1) below especially in an OLED device or a PLED device, there can be realized excellent EL device characteristics such as low driving voltage, high luminous efficiency and long life.

Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

The invention relates to a crystalline methyl carbamate compound, namely a crystal form of N-[(2S)-1-[(2S)-2-{4-[7-(4-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutyryl]pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)-2H-1,3-benzodioxan-4-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxybutan-2-yl]methyl carbamate dihydrochloride, a pharmaceutical composition containing the crystal form, anda use of the crystal form in preparation of drugs in treatment of hepatitis C virus.

A medicament for preventive and / or therapeutic treatment of irritable bowel syndrome which comprises as an active ingredient a substance selected from the group consisting of an alkylenedioxybenzene derivative represented by the following general formula (I) and a pharmaceutically acceptable salt thereof, and a hydrate thereof and a solvate thereof:wherein m represents an integer of from 2 to 5, and n represents an integer of from 1 to 3 (e.g., 5-[3-[(2S)-(1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxol).

The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: wherein each of R1, R2, R3, R4, x, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors.

Compounds of the formula I:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

By using a charge-transporting thin film which is made of charge-transporting varnish containing, as an electron-acceptor material, a 1,4-benzodioxane sulfonic acid compound represented by the formula (1) below especially in an OLED device or a PLED device, there can be realized excellent EL device characteristics such as low driving voltage, high luminous efficiency and long life.

Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired. The present invention provides a fungicidal composition containing a carboxylic acid amide derivative of the formula (I) or a salt thereof, as an active ingredient: wherein A is phenyl which may be substituted, benzodioxolanyl which may be substituted, or benzodioxanyl which may be substituted; B is 2- or 3-pyridyl which may be substituted; each of R1 and R2 is alkyl, or R1 and R2 may together form a 3- to 6-membered saturated carbon ring, provided that when B is 3-pyridyl which may be substituted, A is phenyl substituted by at least two substituents.

Compounds of the Formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

The invention belongs to the technical field of compound synthesis, and specifically relates to a synthesis method for guanoxan sulfate. The synthesis method comprises the following steps: (1) preparing 2-bromomethyl-1,4-benzodioxane or 2-chloromethyl-1,4-benzodioxane; (2) preparing 1,4-benzodioxin-2-methanamine; and (3) preparing the guanoxan sulfate. Compared to the prior art, the method of the present invention has the following advantages that: the steps are simple, the reaction time is shortened, the yield of the prepared product is high, the purity is high, the method is applicable for the wide application, and the great economic benefits can be provided.

A preventive and / or therapeutic medicament for circadian rhythm sleep disorders such as jet lag syndrome which comprises as an active ingredient an alkylenedioxybenzene derivative represented by the following formula (I) wherein m represent an integer of from 2 to 5, and n represents an integer of from 1 to 3, such as 5-[3-[(2S)-(1,4-benzodioxan-2-yl-methyl)amino]propoxy]-1,3-benzodioxol, or a pharmaceutically acceptable salt thereof.

The invention relates to a pomalidomide derivative. The chemical structure of the pomalidomide derivative is shown as the following formula (I), in the formula (I), R1 is phenyl or 1, 4-benzodioxane,R2 is chlorine or bromine, R3 is hydrogen or a 3-methylbenzonitrile group, and X is a linking group selected from ethylenediamine, propane diamine, butanediamine, pentanediamine, hexamethylenediamine,piperazine succinic acid, piperazine glutaric acid, piperazine diglycolic acid, ethylenediamine succinic acid, ethylenediamine glutaric acid, ethylenediamine diglycolic acid, propane diamine glutaricacid, butanediamine glutaric acid or pentanediamine malonic acid. The pomalidomide derivative disclosed by the invention can inhibit the mutual combination of a programmed cell death receptor 1 / a programmed cell death ligand 1 (PD-1 / PD-L1), can be used for preparing a PD-1 / PD-L1 inhibitor, and has a remarkable effect.

A composition comprising an organic carbonate such as propylene carbonate and O,O-diethyl-O-(2-isopropyl-4-methyl-6-pyrimidinyl)phosphorothioate, S-[1,2-bis(ethoxycarbonyl)ethyl]O,O-dimethylphosphorodithioate, or 6,7,8,9,10, 10-hexachloro-1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepin-3-oxide, and methods thereof.

An 1-amido-3-(2-hydroxyphenoxy)-2-propanol derivative represented by the following formula (1), wherein cycle A may have further 1 to 4 substituents, and said substituent means a substituent selected from the group consisting of saturated or unsaturated C1-4 alkyl group, aralkyl group in which alkyl moiety has 1 to 4 carbon atoms, aryl group, halogen atom, halogenated C1-4 alkyl group, C2-5 alkanoyl group, mono or dialkylcarbamoyl group in which alkyl moiety has 1 to 4 carbon atoms, cyano group and nitro group, and the substituents at positions 3 and 6, or at positions 4 and 5 on the cycle A are different each other. Other ring may be fused at positions 3 and 4, or at positions 5 and 6 on the cycle A to form a condensed polycyclic hydrocarbon with the cycle A. R1 is alkanoyl group or aroyl group, and R2 is hydrogen atom, alkanoyl group or aroyl group, or R1 and R2 may be combined together with the N atom to form a cyclic imido group, which is useful as an intermediate of medicines, etc.

The invention provides compounds of the Formula:that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

The invention relates to a one-pot preparation method of 2,2-difluoro-1,3-benzodioxole. The one-pot preparation method of 2,2-difluoro-1,3-benzodioxole is characterized by comprising the following steps: adding piperonyl cyclonene, phosphorus oxychloride and phosphorus pentachloride in a lined polytetrafluoroethylene stainless steel bottle, rising temperature to reflux, ending the reaction when the content of piperonyl cyclonene taken as a raw material is detected to be less than 0.2% by GC, carrying out vacuum rectification on a reaction solution to distill off phosphorus trichloride which is a byproduct and phosphorus oxychloride taken as a solvent; cooling to the temperature of 0 to 5 DEG C after the vacuum rectification is finished, dropwise adding hydrogen fluoride liquid at the vacuum degree of minus 0.1 to minus 0.09MPa, then carrying out heat preservation and releasing the byproduct, namely hydrogen chloride; then dropwise adding a saturated sodium carbonate aqueous solution, adjusting the PH value of the solution to be 6.5 to 7.5, stirring and standing to be stratified, taking an organic layer and distilling to obtain a finished product, namely 2,2-difluoro-1,3-benzodioxole which is colorless and transparent liquid. The one-pot preparation method of 2,2-difluoro-1,3-benzodioxole disclosed by the invention has the advantages of low reaction temperature, high safety and improved yield.

PCT No. PCT / JP98 / 02081 Sec. 371 Date Jan. 11, 1999 Sec. 102(e) Date Jan. 11, 1999 PCT Filed May 12, 1998 PCT Pub. No. WO98 / 51680 PCT Pub. Date Nov. 19, 1998An industrial method for preparation of a 1,4-benzodioxane derivative (1), which comprises reacting a diol compound (2) with a carbonating agent to prepare a carbonate compound (3) and after removal of the protective group, cyclizing it by heating or by treating with a base or a fluoride salt.

The invention discloses a preparation method of a thiazole derivative which is (4-(7-chlorine-2,3-dihydrobenzo[b][1,4]dioxane-6-yl)thiazole-2-yl)methanol. The method is characterized by taking 4-chlorocatechol as a starting raw material, carrying out cyclization, Friedel-Crafts reaction, cyclization, deacetalization protection and reduction to obtain the target product. The compound is used as animportant medical intermediate.

Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

A simple and safe method for producing optically active 1,4-benzodioxane derivatives useful as intermediates for pharmaceuticals and the like from inexpensive materials is provided. An optically active triol compound (5) produced by reaction of catechol (2) and optically active 3-halogeno-1,2-propanediol (3) is sulfonylated to form optically active trisulfonate (6), followed by cyclization with a base to yield optically active 1,4-benzodioxane (1).

Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

The invention belongs to the technical field of organic drug synthesis, and particularly relates to a guanoxan sulfate synthesis method. The method comprises steps as follows: 1), 2-hydroxymethyl-1,4-benzodioxane and thionyl chloride have a chlorination reaction under the condition of existence of a solvent I, and 2-chloromethyl-1,4-benzodioxane is obtained; 2), 2-chloromethyl-1,4-benzodioxane and guanidine are condensed under the condition of existence of alkali and a solvent II, guanoxan is obtained, guanoxan and sulfuric acid are salified, and a finished product guanoxan sulfate is obtained. According to the guanoxan sulfate synthesis method, technological synthesis steps are simple, a route is short, raw material toxicity is relatively lower, and the yield and the purity of the product are high.